Avadel Pharmaceuticals (AVDL) Equity Average (2016 - 2022)
Historic Equity Average for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to -$7.9 million.
- Avadel Pharmaceuticals' Equity Average fell 10724.03% to -$7.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$7.9 million, marking a year-over-year decrease of 10724.03%. This contributed to the annual value of $120.3 million for FY2021, which is 8074.35% up from last year.
- According to the latest figures from Q3 2022, Avadel Pharmaceuticals' Equity Average is -$7.9 million, which was down 10724.03% from $26.0 million recorded in Q2 2022.
- Over the past 5 years, Avadel Pharmaceuticals' Equity Average peaked at $176.7 million during Q3 2020, and registered a low of -$28.1 million during Q4 2019.
- Moreover, its 5-year median value for Equity Average was $34.3 million (2018), whereas its average is $58.8 million.
- Its Equity Average has fluctuated over the past 5 years, first tumbled by 20575.08% in 2019, then skyrocketed by 1031736.4% in 2021.
- Over the past 5 years, Avadel Pharmaceuticals' Equity Average (Quarter) stood at $34.3 million in 2018, then tumbled by 181.96% to -$28.1 million in 2019, then soared by 693.76% to $166.7 million in 2020, then crashed by 46.86% to $88.6 million in 2021, then plummeted by 108.9% to -$7.9 million in 2022.
- Its Equity Average was -$7.9 million in Q3 2022, compared to $26.0 million in Q2 2022 and $66.7 million in Q1 2022.